Technology ID
              TAB-3436
          Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation
E-Numbers
          E-125-2018-0
          E-125-2018-1
          E-125-2018-2
              Lead Inventor
          Fessler, Michael
              Lead IC
          NIEHS
              Co-Inventors
          Williams, Carmen
          Lin, Wan-Chi
              ICs
          NIEHS
              Applications
          Therapeutics
          Diagnostics
              Therapeutic Areas
          Ophthalmology
          Oncology
          Infectious Disease
          Immunology
          Endocrinology
          Dental
          Cardiology
              Development Stages
          Pre-Clinical (in vitro)
              Research Products
          Antibodies
              During lung infection, bloodstream neutrophils (PMNs) responding to infection travel to the airspace lumen. Although successful arrival of microbicidal PMNs to the airspace is essential for host defense against inhaled pathogens, excessive accumulation of PMNs in the lung contributes to the pathogenesis of several prevalent lung disorders, including acute lung injury, bronchiectasis, and COPD. Unfortunately, there is no treatment for controlling PMN accumulation in the lung.
NIEHS researchers identified epithelial membrane protein 2 (EMP2) as a lung epithelial protein that regulates PMN entry into the inflamed airspace. EMP2 knockout mice have reduced PMN accumulation and exhibit increased survival during bacterial infection.
      
  NIEHS researchers identified epithelial membrane protein 2 (EMP2) as a lung epithelial protein that regulates PMN entry into the inflamed airspace. EMP2 knockout mice have reduced PMN accumulation and exhibit increased survival during bacterial infection.
Commercial Applications
              An EMP2 inhibitor can be developed for the treatment or prophylaxis for a wide variety of neutrophil-dependent lung disorders, such as:.
                - acute lung injury
- pneumonia (bacterial, viral, fungal)
- bronchiectasis
- COPD and asthma
- radiation- or chemotherapeutic-induced pneumonitis
- idiopathic or induced interstitial lung disease
- bronchopulmonary dysplasia
- lung transplant rejection
Competitive Advantages
              - EMP2 can selectively target PMN accumulation in the lung, rather than broadly affecting PMN trafficking through all tissues
Licensing Contact: